Myostatin serum concentrations are correlated with the severity of knee osteoarthritis

Zhao, Chang; Shao, Yan; Lin, Chuangxin; Zeng, Chun; Fang, Hang; Pan, Jinhe; Cai, Daozhang

doi:10.1002/jcla.22094

Cited by 14 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports point out a decreased concentration of serum myostatin in the acute phase and a reverse effect in the chronic phase of burn patients [ 37 , 38 ]. Zhao et al [ 39 ] revealed that serum myostatin levels are higher in patients with knee osteoarthritis. Baczek et al [ 40 ] pointed out the difficulties in interpreting myostatin levels in various disease statuses and in understanding the interrelationship between physiological variables (such as age, sex and physical activity).…”

Section: Discussionmentioning

confidence: 99%

Myostatin/Appendicular Skeletal Muscle Mass (ASM) Ratio, Not Myostatin, Is Associated with Low Handgrip Strength in Community-Dwelling Older Women

Choi

Lee

Kang

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background/Aims: Elevated levels of serum myostatin have been proposed as a biomarker for sarcopenia. Recent studies have shown that elevated level of serum myostatin was associated with physical fitness and performance. This study aimed to examine the significance of myostatin in the association between muscle mass and physical performance in the elderly. Methods: This cross-sectional study is based on the Korean Frailty and Aging Cohort study involving 1053 people aged 70 years or over. Anthropometric, physical performance, and laboratory data were collected. Results: The mean age of the participants was 75.8 years, and 50.7% of them were female. Serum myostatin levels in men (3.7 ± 1.2 vs. 3.2 ± 1.1 ng/mL, p < 0.001) were higher compared with that in women. Serum myostatin level was associated with appendicular skeletal muscle mass (ASM) index and eGFR by cystatin C. Serum myostatin/ASM ratio was associated with handgrip strength in women. Conclusion: Higher serum myostatin levels were related with higher muscle mass and better physical performances in the elderly. Serum myostatin/ASM ratio may be a predictor for physical performance rather than myostatin.

show abstract

Section: Discussionmentioning

confidence: 99%

Myostatin/Appendicular Skeletal Muscle Mass (ASM) Ratio, Not Myostatin, Is Associated with Low Handgrip Strength in Community-Dwelling Older Women

Choi

Lee

Kang

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Due to its potential role in the aforesaid disorder, myostatin could be investigated regarding the prediction of the long-term muscle strength, as well as the therapy improving condition of patients after severe burn injuries. Research by Zhao et al, proved that serum myostatin levels are higher in patients with knee osteoarthritis [ 160 ]. A novel finding made by Su et al, demonstrated in vivo that overexpression of myostatin induces robust expression of TNF-α in rheumatoid arthritis synovial fibroblasts, leading to chronic synovitis [ 161 ].…”

Section: Factors Affecting Myostatin Concentrationmentioning

confidence: 99%

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

2020

View full text Add to dashboard Cite

Sarcopenia is a geriatric syndrome with a significant impact on older patients’ quality of life, morbidity and mortality. Despite the new available criteria, its early diagnosis remains difficult, highlighting the necessity of looking for a valid muscle wasting biomarker. Myostatin, a muscle mass negative regulator, is one of the potential candidates. The aim of this work is to point out various factors affecting the potential of myostatin as a biomarker of muscle wasting. Based on the literature review, we can say that recent studies produced conflicting results and revealed a number of potential confounding factors influencing their use in sarcopenia diagnosing. These factors include physiological variables (such as age, sex and physical activity) as well as a variety of disorders (including heart failure, metabolic syndrome, kidney failure and inflammatory diseases) and differences in laboratory measurement methodology. Our conclusion is that although myostatin alone might not prove to be a feasible biomarker, it could become an important part of a recently proposed panel of muscle wasting biomarkers. However, a thorough understanding of the interrelationship of these markers, as well as establishing a valid measurement methodology for myostatin and revising current research data in the light of new criteria of sarcopenia, is needed.

show abstract

“…In skeletal muscle, BDNF is involved in the regulation and survival of motoneurons, in the development and differentiation of myoblasts, in the interaction between immune cells and muscle cells (43). However, myostatin and follistatin are altered in osteoarthritis (44, 45), GDF-15 in cardiovascular disease (46), and BDNF in mood disorders (47) and deregulated heart autonomic system (48).…”

Section: Biomarkers Of Sarcopeniamentioning

confidence: 99%

The Biological Foundations of Sarcopenia: Established and Promising Markers

et al. 2019

View full text Add to dashboard Cite

Sarcopenia, the progressive loss of muscle mass and strength, is one of the major health issues in older adults, given its high prevalence accompanied by huge clinical and socioeconomic implications. Age-related changes in skeletal muscle can be attributed to mechanisms both directly and indirectly related to muscle homeostasis. Indeed, a wide spectrum of age-related modifications in the organism was shown to play a key role in the pathogenesis of sarcopenia. Not surprisingly, sarcopenia has sometimes been indicated as a syndrome stemming from the aging process, and not as univocal standalone disease. Due to the multidimensionality of sarcopenia, a single biomarker approach is not enough to explain the biology of this condition. The aim of this review is to suggest innovative and promising sarcopenia markers investigating the link between skeletal muscle and brain. Indeed, as a neurological origin of sarcopenia has been hypothesized, a new perspective on sarcopenia biomarkers may focus on the dysfunction of the neuromuscular junctions (NMJs). The core SNARE synaptosomal-associated protein of 25 kDa (SNAP25) accumulates in the plasma membrane of nerve terminals at NMJs and regulates exocytosis at peripheral and central synapses. Interestingly, mice studies have shown that SNAP25 affects the neuromuscular function. SNARE complex and, in particular, SNAP25 may represent a promising pathway to explore the molecular and cellular mechanisms regulating muscular homeostasis and concur at profiling the sarcopenia biological background.

show abstract

Myostatin serum concentrations are correlated with the severity of knee osteoarthritis

Abstract: Serum and SF myostatin concentrations were correlated with the presence and severity of knee OA.

Cited by 14 publications

References 19 publications

Myostatin/Appendicular Skeletal Muscle Mass (ASM) Ratio, Not Myostatin, Is Associated with Low Handgrip Strength in Community-Dwelling Older Women

Myostatin/Appendicular Skeletal Muscle Mass (ASM) Ratio, Not Myostatin, Is Associated with Low Handgrip Strength in Community-Dwelling Older Women

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

The Biological Foundations of Sarcopenia: Established and Promising Markers

Contact Info

Product

Resources

About